Vidac Pharma reels in $9 mln Series A

Jerusalem-based Vidac Pharma, a developer of drugs that treat cancer and oncodermatology disease, has raised $9 million in Series A financing. Israel Biotech Fund led the round with participation from other investors that included Mivtach Shamir Holdings. In addition to the funding, Dr. Robert Spiegel and Ed Saltzman of Israel Biotech Fund’s venture advisory team have been appointed to Vidac’s board of directors.

Source: Press Release